Name of journal: World Journal of Clinical Cases  
Manuscript NO: 64569  
Title: Successful response to camrelizumab in metastatic bladder cancer: A case report  
Reviewer’s code: 00160258  
Position: Editorial Board  
Academic degree: MD  
Professional title: Professor  
Reviewer’s Country/Territory: India  
Author’s Country/Territory: China  
Manuscript submission date: 2021-03-11  
Reviewer chosen by: Jin-Lei Wang  
Reviewer accepted review: 2021-03-12 03:45  
Reviewer performed review: 2021-03-12 03:48  
Review time: 1 Hour  

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Peer-reviewer statements: Peer-Review: Yes | Anonymous | No  
Conflicts-of-Interest: Yes | No
SPECIFIC COMMENTS TO AUTHORS

English language needs to be improved. Rest it is a good paper worth publication.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 64569

Title: Successful response to camrelizumab in metastatic bladder cancer: A case report

Reviewer’s code: 00740391

Position: Editorial Board

Academic degree: FRCS (Hon), MBBS, MD

Professional title: Doctor, Senior Lecturer

Reviewer’s Country/Territory: Australia

Author’s Country/Territory: China

Manuscript submission date: 2021-03-11

Reviewer chosen by: Jin-Lei Wang

Reviewer accepted review: 2021-04-20 01:59

Reviewer performed review: 2021-04-21 02:06

Review time: 1 Day

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>statements</td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

Thank you for the article - please provide details of the histological findings on the cystectomy specimen and if there was a biopsy of the metastatic deposit - please include images. What were the side effects of the drug regimen? When would the authors suggest use of this drug in the multitude of treatment options - please add a paragraph to the text.
### PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases  
**Manuscript NO:** 64569  
**Title:** Successful response to camrelizumab in metastatic bladder cancer: A case report  
**Reviewer’s code:** 05121314  
**Position:** Associate Editor  
**Academic degree:** FEBS, MD, PhD  
**Professional title:** Surgeon  
**Reviewer’s Country/Territory:** Italy  
**Author’s Country/Territory:** China  
**Manuscript submission date:** 2021-03-11  
**Reviewer chosen by:** Jin-Lei Wang  
**Reviewer accepted review:** 2021-04-21 16:28  
**Reviewer performed review:** 2021-04-26 12:39  
**Review time:** 4 Days and 20 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-review statements</td>
<td>Peer-Review: [ ] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

I enjoyed reading this case. I would recommend to also determine whether risk factors for urothelial carcinoma were present in the patient's history and whether they influenced the possible chemotherapy response.